Long- Versus Short-Acting β2-Agonists - Implications for Drug Therapy

Drugs

Volumn 47, Issue 2, 1994, Pages 207-222

  Boulet, Louis Philippe ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; ANTIINFLAMMATORY AGENT; BAMBUTEROL; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BITOLTEROL; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FENOTEROL; FORMOTEROL; IPRATROPIUM BROMIDE; ISOPRENALINE; KETOTIFEN; LONG ACTING DRUG; PIRBUTEROL; PROCATEROL; RIMITEROL; SALBUTAMOL; SALMETEROL; STEROID; TERBUTALINE; THEOPHYLLINE;

AIRWAY RESISTANCE; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHODILATATION; CARDIOVASCULAR EFFECT; COHORT ANALYSIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG SAFETY; DRUG TOLERANCE; EDITORIAL; EXERCISE INDUCED ASTHMA; GLUCOSE BLOOD LEVEL; HEART PALPITATION; HUMAN; HYPERVENTILATION; HYPOKALEMIA; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; LYMPHOCYTE; MORTALITY; ORAL DRUG ADMINISTRATION; PEAK EXPIRATORY FLOW; PHARMACODYNAMICS; RECEPTOR AFFINITY; RECEPTOR SENSITIVITY; RESPIRATORY ARREST; RISK FACTOR; SMOOTH MUSCLE RELAXATION; TACHYCARDIA; TREMOR;

ADRENERGIC BETA-AGONISTS; ASTHMA; BRONCHODILATOR AGENTS; DELAYED-ACTION PREPARATIONS; HUMAN;

EID: 0028087175     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199447020-00001     Document Type: Article

References (187)

1. A study of adrenotropic receptors
2. Position statement: inhaled β2-adrenergic agonists in asthma
3. Pharmacology of formoterol: an innovative bronchodilator
4. Long acting inhaled beta-adrenoceptor agonists: the comparative pharmacology of formoterol and salmeterol
5. Duration of protection by inhaled salmeterol in exercise-induced asthma
6. Inhaled formeterol during one year in asthma: a comparison with salbutamol
7. Formoterol, a new long-acting bronchodilator for inhalation
8. Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo
9. The effect of ipratropium and fenoterol on methacholine and histamineinduced bronchoconstriction
10. New concepts in the pathogenesis of bronchial hyperresponsiveness and asthma
11. New drugs for asthma
12. Questions about inhaled β2-agonists in asthma
13. Effect on airway responsiveness of six weeks treatment with salmeterol
14. A comparison of the speeds of action of salmeterol and salbutamol in reversing methacholine-induced bronchoconstriction
15. Formoterol, a new long-acting selective beta 2-adrenergic receptor agonist: double-blind comparison with salbutamol and placebo in children with asthma
16. Formoterol, a new long-acting selective beta 2-agonist, decreases airway responsiveness in children with asthma
17. The protective effect of a β-2 agonist against excessive airway narrowing in response to bronchoconstrictor stimuli in asthma and chronic obstructive lung disease
18. Changes in bronchial reactivity in asthmatic children after treatment with beclomethasone alone or in association with salbutamol
19. Long-term regularly inhaled salbutamol
20. New pharmacologic agents in the treatment of asthma
21. Salmeterol: long-term studies in children
22. Comparative efficacy of salbutamol, ipratropium and cromoglycate in the prevention of the bronchospasm induced by exercise and hyperosmolar challenges
23. Placebo controlled comparison of the bronchodilator performance of salmeterol and salbutamol over 12 hours
24. A comparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol
25. Guidelines for the management of asthma: a summary
26. Tolerance to beta-agonists in asthma therapy
27. Dose related effects of salbutamol and ipratropium bromide on airway calibre and reactivity in subjects with asthma
28. A twelve month comparison of salmeterol with salbutamol in asthmatic patients: European Study Group
29. Salmeterol xinafoate: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease
30. Feneterol and fatal asthma. Correspondence
31. The β-agonist dilemma
32. Salmeterol: a potent and longacting inhibitor of inflammatory mediator release from human lung
33. A singledose comparison of inhaled albuterol and two formulations of salmeterol on airway reactivity in asthmatic subjects
34. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment
35. Prolonged bronchodilating effect of formoterol versus procaterol in bronchial asthma
36. Long-term effects of a long-acting beta 2-adrenoreceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma
37. Respiratory arrests in young asthmatics on salmeterol
38. Characteristics of bronchodilating activity of formoterol
39. Beta-adrenergic tachyphyIaxis (desensitization) and functional antagonism
40. Guidelines for management of asthma in adults: I. chronic persistent asthma
41. Cardiovascular and hypokalemic effects of inhaled salbutamol, fenoterol, and isoprenaline
42. Prescribed fenoterol and death from asthma in New Zealand 1981-83: case control study
43. Salmeterol: a four week study of a long-acting beta-adrenoreceptor agonist for the treatment of reversible airway disease
44. The influence of inhaled salmeterol on bronchial inflammation. A bronchoalveolar lavage study in patients with bronchial asthma
45. Bronchoalveolar lavage studies
46. Time course of bronchodilating effect of inhaled formoterol, a potent and long acting sympathomimetic
47. The effect of inhaled salmeterol on methacholine responsiveness in subjects with asthma up to 12 hours
48. Effects of salmeterol on nocturnal asthma
49. Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding by severity?
50. Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use
51. Formoterol: a review of its pharmacological properties and therapeutic efficacy in reversible obstructive airways disease
52. Salmeterol and salbutamol: long-term efficacy and safety
53. Comparison of single dose formoterol and terbutaline on the immediate asthmatic response to allergen provocation testing
54. Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a long acting inhaled beta 2 agonist
55. The cardiovascular effects of beta adrenergic agonist drugs administered by nebulisation
56. A study with cumulative doses of formoterol in children with asthma
57. A single-dose comparison of inhaled albuterol and two formulations of salmeterol on airway reactivity in asthmatic subjects
58. Twelve hours’ bronchodilating effect of inhaled formoterol in children with asthma: a double-blind cross-over study versus salbutamol
59. Prescribed fenoterol and death from asthma in New Zealand, 1981–1987: a further case control study
60. The influence of long-acting β2-agonist salmeterol xinafoate
61. Prevention of exercise induced asthma by inhaled salmeterol xinafoate
62. Prolonged effect against exercise-induced bronchospasm: salmeterol versus sodium cromoglycate
63. Comparison of a β2 agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma
64. The assessment of asthma: a conference report
65. Airway response to salbutamol: effect of regular salbutamol inhalations in normal, atopic, and asthmatic subjects
66. Effect of inhaled formoterol versus terbutaline on respiratory function in moderate bronchial asthma
67. Long-term efficacy of formoterol compared to salbutamol
68. Protective effect and duration of action of inhaled formoterol and salbutamol on exercise-induced asthma in children
69. Rise and fall of asthma mortality in England and Wales in relation to use of pressurised aerosols
70. Diagnosis and treatment of asthma
71. On the predictive value of experiments in vitro in the evaluation of the effect and duration of bronchodilator drugs for local administration
72. The pharmacology of salmeterol
73. Salmeterol: a novel drug for the treatment of asthma
74. The preclinical pharmacology of salmeterol: bronchodilator effects
75. New β2-adrenergic agonists aerosols
76. Dose-response study of inhaled salmeterol in asthmatic patients with 24-hour spirometry and Holter monitoring
77. Effect of long-term treatment with inhaled corticosteroids and β-agonists on the bronchial responsiveness in children with asthma
78. A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma
79. Sustained improvement in asthma with long-term use of formoterol fumerate
80. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline
81. β-Agonists in asthma-state of the art: report on a Royal Society of Medicine seminar
82. A comparative study of the effects of an inhaled corticosteroids, budesonide, and of a β2 agonist, terbutaline, on airway inflammation in newly-diagnosed asthma
83. Differentiation of receptor systems activated by sympathomimetic amines
84. Long-term studies on long-acting sympathomimetics
85. Beta-2 receptor agonists in asthma: a comparison
86. Preventative effect of formoterol aerosol in methacholine-induced bronchoconstriction
87. The effects of beta 2-adrenoceptor agonists and a corticosteroids budesonide on the secretion of inflammatory mediators from monocytes
88. Risks versus benefits of inhaled β2-agonists in the management of asthma
89. Subsensitivity of β-adrenoceptor responses in asthmatic patients taking regular low dose inhaled salbutamol
90. Basic pharmacology of new long-acting sympathomimetics
91. Long-acting beta 2-adrenoceptor agonists: a new perspective in the treatment of asthma
92. Formoterol fumarate, a new beta 2-adrenoceptor agonist: acute studies of selectivity and duration of effect after inhaled and oral administration
93. Beta-agonists: still more friends than foes
94. Twelve months treatment with inhaled salmeterol in asthmatic patients: effects of β2-receptor function and inflammatory cells
95. Salmeterol: an inhaled β2-agonist with prolonged duration of action
96. The effect of maximal doses of formoterol and salbutamol from a metered dose inhaler on pulse rates, ECG, and serum potassium concentrations
97. Formoterol as dry powder inhalation: a dose-finding study in comparison with formoterol metered dose inhaler and placebo
98. Formoterol suspension aerosol: comparison with formoterol solution aerosol for 12 weeks in asthmatic patients
99. Bronchodilator effect of inhaled formoterol vs salbutamol over 12 hours
100. Formoterol in the treatment of nocturnal asthma
101. Formoterol, a new inhaled beta-2 adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction
102. Salmeterol, a new inhaled beta 2-adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction
103. Prophylaxis of exercise-induced asthma with inhaled formoterol, a long-acting beta-2 adrenergic agonist
104. Formoterol, a new long-acting beta 2 agonist, inhaled twice daily, in stable asthmatic subjects
105. Is current treatment increasing asthma mortality and morbidity?
106. Respiratory arrest in near-fatal asthma
107. Clinical pharmacokinetics of β-agonists
108. A European respiratory review on salmeterol
109. Salmeterol versus slow-release theophylline combined with ketotifen in nocturnal asthma: a multicentre trial
110. Regular inhaled beta-adrenergic agonists in the treatment of bronchial asthma: beneficial or detrimental?
111. Investigations into factors determining the duration of action of the beta 2-adrenoceptor agonist, salmeterol
112. Concomitant use of beta adrenergic agonists and methylxanthines
113. Mechanisms of β-adrenergic receptor regulation in lung and its implication for physiological responses
114. Effect of formoterol, a long-lasting beta 2-adrenoceptor agonist, against methacholine-induced bronchoconstriction
115. Salmeterol protects against hyperventilation-induced bronchoconstriction over 12 hours
116. Late asthmatic responses
117. Inhibition of the bronchial response to respiratory heat exchange by increasing doses of terbutaline sulphate
118. Tolerance to bronchodilator effects of inhaled β2-agonists in asthma
119. Fenoterol and fatal asthma
120. One explanation of the asthma paradox: inhibition of natural anti-inflammatory mechanisms by beta-2-agonists
121. Beta agonists and the asthma paradox
122. Why β-agonists should not be used regularly
123. Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstruction airways disease, a 3 month comparison of the efficacy and safety of twice-daily salmeterol (100 micrograms) with salmeterol (50 micrograms)
124. Late asthmatic reaction decreased after pretreatment with salbutamol and formoterol, a new long-acting beta 2-agonist
125. Intermittent and continous salbutamol rotacaps inhalation in asthmatic patients
126. Protective effect and duration of action of formoterol aerosol on exercise-induced asthma
127. Onset of action of beta-2-agonists by comparison of inhaled formoterol vs inhaled salbutamol. Abstract
128. Beta-agonists and asthma mortality: déjà vu
129. Casecontrol study of prescribed fenoterol and death from asthma in New Zealand 1977-1981
130. A comparison of salmeterol with albuterol in the treatment of mild to moderate asthma
131. The effect of salmeterol on the early- and late-phase reaction to bronchial allergen and postchallenge variation in bronchial reactivity, blood eosinophils, serum eosinophil cationic protein and serum eosinophil protein X
132. A comparison of oral procaterol an albuterol in reversible airflow obstruction
133. Fenoterol and fatal asthma. Correspondence
134. Formoterol a new long-acting β-2 agonist for inhalation twice daily compared with salbutamol in the treatment of asthma
135. The challenge of long-acting beta-adrenoceptor agonists
136. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma
137. Prolonged protection against methacholine-induced broncho-constriction by the inhaled β-2 agonist formoterol
138. Beta 2 agonists and asthma
139. Assessment of tachyphylaxis following prolonged therapy with inhaled albuterol aerosol
140. The influence of salmeterol xinafoate on mucosal inflammation in asthma
141. Sudden cardiac death in bronchial asthma, and inhaled beta-adrenergic agonists
142. Cathecholamine cardiotoxicity
143. Multicenter 1-year trial on formoterol, a new long-acting beta 2-agonist, in chronic obstructive airway disease
144. Regular inhaled β-agonist treatment in bronchial asthma
145. Regular versus symptomatic aerosol bronchodilator treatment of asthma
146. Asthma exacerbations in patients taking regular salmeterol, or salbutamol for symptoms
147. The clinical evaluation of formoterol (BD 40A) in bronchial asthma with long term administration and in chronic obstructive pulmonary disease with short term administration
148. Asthma deaths and bronchodilator aerosols
149. Bronchodilator and bronchoprotective effects of salmeterol in young patients with asthma
150. Beta-adrenergic agonists: a problem
151. Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma
152. The use of adrenal substances in the treatment of asthma
153. Preventive effects of inhaled formoterol and salbutamol on histamine-induced bronchoconstriction: a placebo controlled study
154. The use of β-agonists and the risk of death and near death from asthma
155. Failure of salmeterol to inhibit circulating white cell responses and bronchoconstriction induced by platelet activating factor
156. The onset of action of formoterol, a new beta 2 adrenoceptor agonist
157. Beta-agonists: friends or foes?
158. Physiology and pharmacodynamics of beta-adrenergic agonists
159. Long-acting beta 2-agonists
160. Effect of β-agonists and anticholinergic drugs on bronchial reactivity
161. Regular inhaled β agonist in asthma: effects on exacerbations and lung function
162. A comparative study in atopic subjects with asthma of the effects of salmeterol and salbutamol on allergen-induced bronchoconstriction, increase in airway reactivity, and increase in urinary leukotriene E4 excretion
163. Inhaled formoterol inhibits histamine-induced airflow obstruction and airway microvascular leakage
164. Comparison for four weeks’ treatment with fenoterol and terbutaline aerosols in adult asthmatics: a double-blind crossover study
165. Protection against allergen-induced asthma by salmeterol
166. The inhibitory effect of nebulized albuterol on the early and late asthmatic reactions and increase in airway responsiveness provoked by inhaled allergen in asthma
167. Onset of action and duration of effect of formoterol and salmeterol compared to salbutamol in isolated guinea pig trachea with or without epithelium
168. Inhaled salmeterol and salbutamol in asthmatic patients: an evaluation of asthma symptoms and the possible development of tachyphy Iaxis
169. Salmeterol, a new long acting β2 ad-renoreceptor agonist: a comparison with salbutamol in adult asthmatic patients
170. Evaluation of oral fenoterol in chronic asthmatic patients
171. Addition of terbutaline to optimal theophylline therapy: double-blind crossover study in asthmatic patients
172. Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol
173. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline
174. Effect of a single dose of inhaled salmeterol on baseline airway caliber and methacholine-induced airway obstruction in asthmatic children
175. Formoterol and salbutamol metered aerosols: comparison of a new and an established beta-2 agonist for their bronchodilating efficacy in the treatment of childhood bronchial asthma
176. Efficacy of formoterol metered aerosol in children
177. Asthma control during and after cessation of regular beta2 agonist treatment
178. Formoterol, a new long-acting beta-2 agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma
179. Aerosolized terbutaline in asthmatics: development of subsensitivity with long-term administration
180. Salmeterol, inhibiting or masking the late asthmatic reaction after HDM challenge
181. Rapid onset of action of inhaled formoterol in asthmatic patients
182. Inhibition by salmeterol of increased vascular permeability and granulocyte accumulation in guinea-pig lung and skin
183. Paradoxical bronchoconstriction in asthmatic patients after salmeterol by metered dose inhaler
184. Formoterol compared with beclomethasone and placebo on allergen-induced asthmatic responses
185. Beta-adrenergic agonist toxicity: less of a problem, more of a perception